Comparison
While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768.
While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, Exenatide is a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67.
BPC-157 is 15 amino acids long, whereas Exenatide is longer as it has a length of 39 amino acids. BPC-157 is made up of a sequence of Glycine, Glutamic acid, Proline, Proline, Proline, Glycine, Lysine, Proline, Alanine, Aspartic acid, Aspartic acid, Alanine, Glycine, Leucine, Valine. Exenatide is made up of a sequence of sequence data not available in the current dataset.
BPC-157
Not assigned in the current dataset.
Exenatide
Not assigned in the current dataset.